Want to see OBIO full AI Analyst Report?
OBIO Stock Chart & Stats
$5.36
$0.10(2.75%)
At close: 4:00 PM EDT
$5.36
$0.10(2.75%)
Day’s Range― - ―
52-Week Range$3.06 - $6.50
Previous Close$3.74
Volume149.34K
Average Volume (3M)334.06K
Market Cap
$355.22M
Enterprise Value$246.24M
Total Cash (Recent Filing)$109.96M
Total Debt (Recent Filing)$70.76M
Price to Earnings (P/E)―
Beta1.70
Next Earnings
Nov 16, 2026EPS Estimate
-0.4Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-0.99
Shares Outstanding60,105,050
10 Day Avg. Volume271,324
30 Day Avg. Volume334,057
Financial Highlights & Ratios
PEG Ratio0.11
Price to Book (P/B)3.13
Price to Sales (P/S)5.92
P/FCF Ratio-4.01
Enterprise Value/Market Cap0.69
Enterprise Value/Revenue7.70
Enterprise Value/Gross Profit7.75
Enterprise Value/Ebitda-4.31
Forecast
1Y Price Target
$11.20Price Target Upside108.96% Upside
Rating ConsensusStrong Buy
Number of Analyst Covering5
EPS Forecast (FY)-1.52
Revenue Forecast (FY)$454.00K
Bulls Say, Bears Say
Bulls Say
High-margin Revenue ScaleRevenue has scaled materially from roughly $2–4 million in 2022–2024 to more than $32 million recently, while gross margins remain near 99%. This indicates a potentially valuable partnership revenue stream that can support future investment as programs advance.
Strategic Partnership ModelRisk-reward sharing partnerships with Medtronic, Terumo and Ligand provide access to established device expertise, strategic capital and commercialization capabilities. This model can accelerate development while avoiding the cost of building a fully integrated global sales infrastructure.
BACKBEAT Trial De-riskingSurpassing the pivotal trial enrollment target is a meaningful development milestone for AVIM Therapy. A completed enrollment base supports planned endpoint analysis, advances the potential regulatory pathway, and moves the program closer to possible commercialization with Medtronic.
Bears Say
Persistent UnprofitabilityDespite the sharp revenue increase, OBIO remains deeply unprofitable, showing that operating expenses are still far ahead of its current revenue base. Continued losses could delay self-funded expansion and require additional financing before the pipeline generates recurring commercial income.
Heavy Cash ConsumptionNegative operating and free cash flow show that reported revenue is not yet translating into internally generated funding. Sustained cash consumption limits financial flexibility and increases the importance of milestones, partnerships or external capital to support ongoing clinical development.
Partner Execution DependenceOBIO’s partnership-driven model reduces the need for a large commercial infrastructure but makes future revenue dependent on third parties’ trial execution, regulatory progress and launch performance. Delays or weaker partner outcomes could postpone milestones and royalties.
Orchestra BioMed Holdings News
OBIO FAQ
What was Orchestra BioMed Holdings’s price range in the past 12 months?
Orchestra BioMed Holdings lowest stock price was $3.06 and its highest was $6.50 in the past 12 months.
What is Orchestra BioMed Holdings’s market cap?
Orchestra BioMed Holdings’s market cap is $355.22M.
When is Orchestra BioMed Holdings’s upcoming earnings report date?
Orchestra BioMed Holdings’s upcoming earnings report date is Nov 16, 2026 which is in 34 days.
How were Orchestra BioMed Holdings’s earnings last quarter?
Orchestra BioMed Holdings released its earnings results on Aug 10, 2026. The company reported -$0.38 earnings per share for the quarter, beating the consensus estimate of -$0.392 by $0.012.
Is Orchestra BioMed Holdings overvalued?
According to Wall Street analysts Orchestra BioMed Holdings’s price is currently Undervalued.
Does Orchestra BioMed Holdings pay dividends?
Orchestra BioMed Holdings does not currently pay dividends.
What is Orchestra BioMed Holdings’s EPS estimate?
Orchestra BioMed Holdings’s EPS estimate is -0.4.
How many shares outstanding does Orchestra BioMed Holdings have?
Orchestra BioMed Holdings has 60,105,050 shares outstanding.
What happened to Orchestra BioMed Holdings’s price movement after its last earnings report?
Orchestra BioMed Holdings reported an EPS of -$0.38 in its last earnings report, beating expectations of -$0.392. Following the earnings report the stock price went down -1.345%.
Which hedge fund is a major shareholder of Orchestra BioMed Holdings?
Currently, no hedge funds are holding shares in OBIO
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Orchestra BioMed Holdings Stock Smart Score
Neutral
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Strong Buy
Average Price Target:
$11.20 (108.96% Upside)
$11.20 (108.96% Upside)
Blogger Sentiment
Bullish
OBIO Sentiment 75%
Sector Average 66%
Sector Average 66%
Insider Transactions
Bought Shares
Worth $58.6K over
the Last 3 Months
the Last 3 Months
Crowd Wisdom
Neutral
Last 7 Days ▼ 1.2%
Last 30 Days ▲ 2.2%
Last 30 Days ▲ 2.2%
Technicals
SMA
Positive
20 days / 200 days
Momentum
87.61%
12-Months-Change
Fundamentals
Return on Equity
-125.93%
Trailing 12-Months
Asset Growth
170.17%
Trailing 12-Months
Learn more about TipRanks Smart Score
Company Description
Orchestra BioMed Holdings
Orchestra BioMed Holdings, Inc. operates as an innovative company in the biomedical sector. Its leading product candidates are BackBeat Cardiac Neuromodulation Therapy (CNT), designed to manage hypertension, and the Virtue Sirolimus AngioInfusion Balloon (SAB), aimed at treating atherosclerotic artery disease. The company's offerings also encompass FreeHold retractors, which are solutions for minimally invasive surgical procedures. Orchestra BioMed has formed key alliances to advance its products: a strategic collaboration with Medtronic focuses on developing and commercializing BackBeat CNT for pacemaker-indicated patients suffering from hypertension. Additionally, a partnership with Terumo Corporation is dedicated to the development and market introduction of Virtue SAB for artery disease. The company's headquarters are located in New Hope, Pennsylvania.
OBIO Stock 12 Month Forecast
Average Price Target
$11.20
▲(108.96% Upside)
Technical Analysis
Cardiff Oncology
―
Greenwich LifeSciences
―
Climb Bio
―
Cognition Therapeutics
―
Pyxis Oncology
―
Ownership Overview
22.04% Insiders
4.88% Mutual Funds
30.15% Other Institutional Investors
35.31% Public Companies and
Individual Investors